Mary Alice Ritter

Title: Mary Alice Ritter: Innovator in Antibody Therapy

Introduction

Mary Alice Ritter is a distinguished inventor based in London, GB. She has made significant contributions to the field of biotechnology, particularly in the development of human mini-antibodies for therapeutic applications. With a total of 4 patents to her name, her work has the potential to impact cancer treatment significantly.

Latest Patents

One of her latest patents is titled "Human mini-antibody cytotoxic for tumor cells which express the ERBB2 receptor." This invention refers to a fully human mini-antibody (scFv), called Erbicin, which is specific for the receptor ErbB2 and exhibits pharmacological, particularly anti-tumor, activity. The mini-antibody has been obtained from a larger phage display library (Griffin 1.) through panning, which involves affinity selection on antigen carried out on live cells expressing various levels of ErbB2. The invention also encompasses the DNA and amino acid sequences of the antibody, the procedure for isolating it, and its therapeutic uses.

Career Highlights

Mary Alice Ritter has worked with notable institutions, including the Royal Postgraduate Medical School of Hammersmith Hospital and Biotechnol S.a. Her innovative research has positioned her as a key figure in the biotechnology sector, focusing on the development of targeted therapies.

Collaborations

Throughout her career, she has collaborated with esteemed colleagues such as Mark Larche and Giuseppe D'Alessio. These partnerships have further enhanced her research and contributed to her success in the field.

Conclusion

Mary Alice Ritter's work in developing human mini-antibodies represents a significant advancement in cancer therapy. Her innovative spirit and dedication to research continue to inspire future developments in biotechnology.